Findings of Misconduct in Science/Research Misconduct, 33763-33764 [2011-14273]

Download as PDF Federal Register / Vol. 76, No. 111 / Thursday, June 9, 2011 / Notices designated the following class of employees as an addition to the SEC: All Atomic Weapons Employer employees who worked in any building at the Wah Chang facility in Albany, Oregon, for the operational period from January 1, 1971 through December 31, 1972, for a number of work days aggregating at least 250 work days, occurring either solely under this employment or in combination with work days within the parameters established for one or more other classes of employees included in the Special Exposure Cohort. This designation became effective on May 29, 2011, as provided for under 42 U.S.C. 7384l(14)(C). Hence, beginning on May 29, 2011, members of this class of employees, defined as reported in this notice, became members of the Special Exposure Cohort. FOR FURTHER INFORMATION CONTACT: Stuart L. Hinnefeld, Director, Division of Compensation Analysis and Support, National Institute for Occupational Safety and Health (NIOSH), 4676 Columbia Parkway, MS C–46, Cincinnati, OH 45226, Telephone 877– 222–7570. Information requests can also be submitted by e-mail to dcas@cdc.gov. John Howard, Director, National Institute for Occupational Safety and Health. combination with work days within the parameters established for one or more other classes of employees included in the Special Exposure Cohort. This designation became effective on May 29, 2011, as provided for under 42 U.S.C. 7384l(14)(C). Hence, beginning on May 29, 2011, members of this class of employees, defined as reported in this notice, became members of the Special Exposure Cohort. FOR FURTHER INFORMATION CONTACT: Stuart L. Hinnefeld, Director, Division of Compensation Analysis and Support, National Institute for Occupational Safety and Health (NIOSH), 4676 Columbia Parkway, MS C–46, Cincinnati, OH 45226, Telephone 877– 222–7570. Information requests can also be submitted by e-mail to DCAS@CDC.GOV. John Howard, Director, National Institute for Occupational Safety and Health. [FR Doc. 2011–14356 Filed 6–8–11; 8:45 am] BILLING CODE 4163–19–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary [FR Doc. 2011–14355 Filed 6–8–11; 8:45 am] BILLING CODE 4163–19–P Findings of Misconduct in Science/ Research Misconduct DEPARTMENT OF HEALTH AND HUMAN SERVICES AGENCY: Final Effect of Designation of a Class of Employees for Addition to the Special Exposure Cohort SUMMARY: Office of the Secretary, HHS. ACTION: Notice. National Institute for Occupational Safety and Health (NIOSH), Department of Health and Human Services (HHS). ACTION: Notice. AGENCY: HHS gives notice concerning the final effect of the HHS decision to designate a class of employees from the Norton Company, Worcester, Massachusetts, as an addition to the Special Exposure Cohort (SEC) under the Energy Employees Occupational Illness Compensation Program Act of 2000. On April 29, 2011, as provided for under 42 U.S.C. 7384q(b), the Secretary of HHS designated the following class of employees as an addition to the SEC: mstockstill on DSK4VPTVN1PROD with NOTICES SUMMARY: All atomic weapons employees who worked in any building or area at the facility owned by the Norton Co. (or a subsequent owner) in Worcester, Massachusetts, during the period from January 1, 1958 through October 10, 1962, for a number of work days aggregating at least 250 work days, occurring either solely under this employment or in VerDate Mar<15>2010 17:56 Jun 08, 2011 Jkt 223001 Notice is hereby given that on May 16, 2011, the Department of Health and Human Services (HHS) Debarring Official, on behalf of the Secretary of HHS, issued a final notice of debarment based on the misconduct in science and research misconduct findings of the Office of Research Integrity (ORI) in the following case: Philippe Bois, Ph.D., St. Jude Children’s Research Hospital: Based on the findings of an investigation report by St. Jude Children’s Research Hospital (St. Jude) and additional analysis conducted by ORI during its oversight review, ORI found that Philippe Bois, Ph.D., former postdoctoral fellow, Department of Biochemistry, St. Jude, engaged in misconduct in science and research misconduct in research funded by National Institute of General Medical Sciences (NIGMS), National Institutes of Health (NIH), grant R01 GM071596, and National Cancer Institute (NCI), NIH, grants P30 CA021765, P01 CA071907, R01 CA072996, and R01 CA100603. ORI found that the Respondent knowingly and intentionally falsified data reported in two (2) papers: PO 00000 Frm 00064 Fmt 4703 Sfmt 4703 33763 1. Bois, P.R., Izeradjene, K., Houghton, P.J., Cleveland, J.L., Houghton, J.A., & Grosveld, C.G. ‘‘FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma.’’ J. Cell. Biol. 170:903–912, September 2005 (hereafter referred to as ‘‘JCB 2005’’); and 2. Bois, P.R., Borgon, R.A., Vornhein, C., & Izard, T. ‘‘Structural dynamics of a-actinin-vinculin interactions.’’ Mol. Cell. Biol. 25:6112–6122, July 2005 (hereafter referred to as ‘‘MCB 2005’’). Specifically, ORI found: • Respondent committed misconduct in science and research misconduct by knowingly and intentionally falsely reporting in Figure 1A of JCB 2005 that FOXO1a was not expressed in cell lysates from alveolar rhabdomyosarcoma (ARMS) tumor biopsies, by selecting a specific FOXO1a immunoblot to show the desired result. • Respondent engaged in misconduct in science and research misconduct by falsifying data presented in Figure 4B of MCB 2005 showing SDS–PAGE for papain digestion of VBS3 and aVBS, by falsely labeling lane 1 to represent papain only digestion, by falsely labeling lane 5 to represent papain digestion of the aVBS peptide, and by falsely inserting a band in lane 3 to represent the aVBS peptide. ORI issued a charge letter enumerating the above findings of misconduct in science and proposing HHS administrative actions. Dr. Bois subsequently requested a hearing before an Administrative Law Judge (ALJ) of the Departmental Appeals Board (DAB) to dispute these findings. ORI moved to dismiss Dr. Bois’ hearing request. On May 16, 2011, the ALJ of the DAB ruled in ORI’s favor and dismissed Dr. Bois’ hearing request. The ALJ found that Dr. Bois had not raised a genuine dispute over facts or law material to the findings of research misconduct and dismissed the hearing request pursuant to 42 CFR 93.504(a)(2), (3). Thus, the misconduct in science and research misconduct findings set forth above became effective, and the following administrative actions have been implemented for a period of three (3) years, beginning on May 26, 2011: (1) Dr. Bois is debarred from eligibility for any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement programs of the United States Government, referred to as ‘‘covered transactions,’’ pursuant to HHS’ Implementation of OMB Guidelines to Agencies on E:\FR\FM\09JNN1.SGM 09JNN1 33764 Federal Register / Vol. 76, No. 111 / Thursday, June 9, 2011 / Notices Governmentwide Debarment and Suspension (2 CFR 376 et seq.); and (2) Dr. Bois is prohibited from serving in any advisory capacity to the U.S. Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800. John Dahlberg, Director, Division of Investigative Oversight, Office of Research Integrity. [FR Doc. 2011–14273 Filed 6–8–11; 8:45 am] BILLING CODE 4150–31–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Committee on Vital and Health Statistics; Meeting mstockstill on DSK4VPTVN1PROD with NOTICES Pursuant to the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) announces the following advisory committee meeting. Name: National Committee on Vital and Health Statistics (NCVHS), Full Committee Meeting. Time and Date: June 15, 2011 9 a.m.–2:30 p.m. June 16, 2011 10 a.m.–3 p.m. June 17, 2011 9 a.m.–5 p.m. Place: Double Tree Hotel, 300 Army Navy Drive, Arlington, VA 22202, (703) 416–4100. Status: Open. Purpose: At this meeting the Committee will hear presentations and hold discussions on several health data policy topics. On the morning of the first day the Committee will hear updates from the Department, the Center for Medicare and Medicaid Services, and the Office of the National Coordinator. A discussion of a letter to the HHS Secretary regarding a report of the President’s Council of Advisors on Science and Technology (PCAST) will also take place. In the afternoon there will be a Standards Subcommittee update and a briefing from the Privacy and Populations Subcommittee Workshop and HHS/IOM Health Data Health Information Forum. On the morning of the second day there will be a review of the final PCAST letters. There will also be a briefing on the Department’s Mulit-Payor Claims Database. Subcommittees will also present their reports. On the third day public and private stakeholders will convene to update the Standards Subcommittee on the status of preparations for the upcoming compliance deadlines for new versions of the updated HIPAA Standards (5010, D.0), a new standard (Medicaid subrogation—NCPDP Version 3.0) and updated code sets under ICD–10. The compliance date for the updated and new standards is January 1, 2012, and the VerDate Mar<15>2010 17:56 Jun 08, 2011 Jkt 223001 compliance deadline for ICD–10 is October 1, 2013. The times shown above are for the full Committee meeting. Subcommittee breakout sessions can be scheduled for late in the afternoon of the first day and second day and in the morning prior to the full Committee meeting on the second day. Agendas for these breakout sessions will be posted on the NCVHS website (URL below) when available. Contact Person for More Information: Substantive program information as well as summaries of meetings and a roster of committee members may be obtained from Marjorie S. Greenberg, Executive Secretary, NCVHS, National Center for Health Statistics, Centers for Disease Control and Prevention, 3311 Toledo Road, Room 2402, Hyattsville, Maryland 20782, telephone (301) 458–4245. Information also is available on the NCVHS home page of the HHS Web site: https:// www.ncvhs.hhs.gov/, where further information including an agenda will be posted when available. Should you require reasonable accommodation, please contact the CDC Office of Equal Employment Opportunity on (301) 458–4EEO (4336) as soon as possible. Dated: June 1, 2011. James Scanlon, Deputy Assistant Secretary for Planning and Evaluation, Science and Data Policy, Office of the Assistant Secretary for Planning and Evaluation. [FR Doc. 2011–14249 Filed 6–8–11; 8:45 am] BILLING CODE 4151–05–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Announcement of Meeting of the Secretary’s Advisory Committee on National Health Promotion and Disease Prevention Objectives for 2020 Department of Health and Human Services, Office of the Secretary, Office of the Assistant Secretary for Health, Office of Disease Prevention and Health Promotion. ACTION: Notice of Meeting. AGENCY: Authority: 42 U.S.C. 217a, Section 222 of the Public Health Service Act, as amended. The Committee is governed by the provision of Public Law 92–463, as amended (5 U.S.C. appendix 2), which sets forth standards for the formation and use of advisory committees. The U.S. Department of Health and Human Services (HHS) announces the next Federal advisory committee meeting regarding the national health promotion and disease prevention objectives for 2020. This meeting will be open to the public and will be held online via WebEx software. The Secretary’s Advisory Committee on National Health Promotion and Disease Prevention Objectives for 2020 will address efforts to implement the SUMMARY: PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 nation’s health promotion and disease prevention objectives and strategies to improve the health status and reduce health risks for Americans by the year 2020. The Committee will provide to the Secretary of Health and Human Services advice and consultation for implementing Healthy People 2020, the nation’s health promotion and disease prevention goals and objectives, and provide recommendations for initiatives to occur during the implementation phase of the goals and objectives. DATES: The Committee will meet on June 30, 2011, from Noon to 2 p.m. Eastern Daylight Time (EDT). ADDRESSES: The meeting will be held on the Internet via WebEx software. For detailed instructions about how to make sure that your windows computer and browser are set up for WebEx, please visit the ‘‘Secretary’s Advisory Committee’’ Web page of the Healthy People Web site (https:// healthypeople.gov/2020/about/ advisory/default.aspx) and click on ‘‘Register to Attend.’’ FOR FURTHER INFORMATION CONTACT: Emmeline Ochiai, Designated Federal Officer, Secretary’s Advisory Committee on National Health Promotion and Disease Prevention Objectives for 2020, U.S. Department of Health and Human Services, Office of the Assistant Secretary for Health, Office of Disease Prevention and Health Promotion, 1101 Wootton Parkway, Room LL–100, Rockville, MD 20852, (240) 453–8259 (telephone), (240) 453–8281 (fax). Additional information is available on the Internet at https:// www.healthypeople.gov. SUPPLEMENTARY INFORMATION: Purpose of Meeting: The Committee will develop its recommendations regarding the Healthy People 2020 Leading Health Indicators. Background: Healthy People provides science-based, 10-year national objectives for promoting health and preventing disease. Since 1979, Healthy People has set and monitored national health objectives to meet a broad range of health needs, encourage collaborations across sectors, guide individuals toward making informed health decisions, and measure the impact of our prevention and health promotion activities. On December 2, 2010, HHS launched Healthy People 2020 and its 42 topic areas. Healthy People 2020 reflects assessments of major risks to health and wellness, changing public health priorities, and emerging issues related to our nation’s health, preparedness, and prevention. Public Participation at Meeting: Members of the public are invited to E:\FR\FM\09JNN1.SGM 09JNN1

Agencies

[Federal Register Volume 76, Number 111 (Thursday, June 9, 2011)]
[Notices]
[Pages 33763-33764]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-14273]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Misconduct in Science/Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that on May 16, 2011, the Department of 
Health and Human Services (HHS) Debarring Official, on behalf of the 
Secretary of HHS, issued a final notice of debarment based on the 
misconduct in science and research misconduct findings of the Office of 
Research Integrity (ORI) in the following case:
    Philippe Bois, Ph.D., St. Jude Children's Research Hospital: Based 
on the findings of an investigation report by St. Jude Children's 
Research Hospital (St. Jude) and additional analysis conducted by ORI 
during its oversight review, ORI found that Philippe Bois, Ph.D., 
former postdoctoral fellow, Department of Biochemistry, St. Jude, 
engaged in misconduct in science and research misconduct in research 
funded by National Institute of General Medical Sciences (NIGMS), 
National Institutes of Health (NIH), grant R01 GM071596, and National 
Cancer Institute (NCI), NIH, grants P30 CA021765, P01 CA071907, R01 
CA072996, and R01 CA100603.
    ORI found that the Respondent knowingly and intentionally falsified 
data reported in two (2) papers:

1. Bois, P.R., Izeradjene, K., Houghton, P.J., Cleveland, J.L., 
Houghton, J.A., & Grosveld, C.G. ``FOXO1a acts as a selective tumor 
suppressor in alveolar rhabdomyosarcoma.'' J. Cell. Biol. 170:903-912, 
September 2005 (hereafter referred to as ``JCB 2005''); and
2. Bois, P.R., Borgon, R.A., Vornhein, C., & Izard, T. ``Structural 
dynamics of [alpha]-actinin-vinculin interactions.'' Mol. Cell. Biol. 
25:6112-6122, July 2005 (hereafter referred to as ``MCB 2005'').

    Specifically, ORI found:
     Respondent committed misconduct in science and research 
misconduct by knowingly and intentionally falsely reporting in Figure 
1A of JCB 2005 that FOXO1a was not expressed in cell lysates from 
alveolar rhabdomyosarcoma (ARMS) tumor biopsies, by selecting a 
specific FOXO1a immunoblot to show the desired result.
     Respondent engaged in misconduct in science and research 
misconduct by falsifying data presented in Figure 4B of MCB 2005 
showing SDS-PAGE for papain digestion of VBS3 and [alpha]VBS, by 
falsely labeling lane 1 to represent papain only digestion, by falsely 
labeling lane 5 to represent papain digestion of the [alpha]VBS 
peptide, and by falsely inserting a band in lane 3 to represent the 
[alpha]VBS peptide.
    ORI issued a charge letter enumerating the above findings of 
misconduct in science and proposing HHS administrative actions. Dr. 
Bois subsequently requested a hearing before an Administrative Law 
Judge (ALJ) of the Departmental Appeals Board (DAB) to dispute these 
findings. ORI moved to dismiss Dr. Bois' hearing request. On May 16, 
2011, the ALJ of the DAB ruled in ORI's favor and dismissed Dr. Bois' 
hearing request. The ALJ found that Dr. Bois had not raised a genuine 
dispute over facts or law material to the findings of research 
misconduct and dismissed the hearing request pursuant to 42 CFR 
93.504(a)(2), (3).
    Thus, the misconduct in science and research misconduct findings 
set forth above became effective, and the following administrative 
actions have been implemented for a period of three (3) years, 
beginning on May 26, 2011:
    (1) Dr. Bois is debarred from eligibility for any contracting or 
subcontracting with any agency of the United States Government and from 
eligibility for, or involvement in, nonprocurement programs of the 
United States Government, referred to as ``covered transactions,'' 
pursuant to HHS' Implementation of OMB Guidelines to Agencies on

[[Page 33764]]

Governmentwide Debarment and Suspension (2 CFR 376 et seq.); and
    (2) Dr. Bois is prohibited from serving in any advisory capacity to 
the U.S. Public Health Service (PHS), including but not limited to 
service on any PHS advisory committee, board, and/or peer review 
committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative 
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 
750, Rockville, MD 20852, (240) 453-8800.

John Dahlberg,
Director, Division of Investigative Oversight, Office of Research 
Integrity.
[FR Doc. 2011-14273 Filed 6-8-11; 8:45 am]
BILLING CODE 4150-31-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.